A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

INTRODUCTION: Tumor immunotherapy is designed to control malignancies through the host immune response but requires circumventing tumor-dysregulated immunomodulation through immunostimulation, relieving immunorepression, or a combination of both approaches. Here we designed and characterized cavroto...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Weston L., Lorch, Ulrike, Mix, Scott, Bexon, Alice S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792500/
https://www.ncbi.nlm.nih.gov/pubmed/36582243
http://dx.doi.org/10.3389/fimmu.2022.1073777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792500/
https://www.ncbi.nlm.nih.gov/pubmed/36582243
http://dx.doi.org/10.3389/fimmu.2022.1073777

Ejemplares similares